News
Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high estimate of $65.00, and a low estimate of $54.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.16%.
Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...
Over the past five years, it posted a negative one-day return in 55% of cases, with a median drop of 3.0% and a maximum ...
Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.
The stock's rise snapped a four-day losing streak.
Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...
The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan
Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...
In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...
Stocktwits on MSN18h
Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The DipShares of Bristol Myers Squibb (BMY) fell more than 4% after the closing bell on Tuesday after the biopharma company reported ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback